GLP-1 Medications Explained: Ownership, Types & Genetic Factors

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists are manufactured by a small number of pharmaceutical companies, with Novo Nordisk and Eli Lilly dominating the market. These include branded products like Ozempic, Wegovy, Zepbound, and Mounjaro, as well as compounded formulations from licensed 503A pharmacies. Understanding ownership structures and clinical differences is essential before initiating therapy.

Beyond identifying which company manufactures a GLP-1 medication, patients benefit from understanding how individual genetic factors in peptide pathways may influence treatment response. PlexusDx emphasizes precision-wellness by helping patients evaluate whether genetic insights paired with clinical guidance can support more personalized medication conversations with their provider.

The Major Manufacturers of GLP-1 Medications

Novo Nordisk leads the GLP-1 market with semaglutide (Ozempic for diabetes, Wegovy for weight loss). Eli Lilly manufactures tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) and dulaglutide (Trulicity). Viking Therapeutics recently developed retatrutide, a triple agonist, expanding treatment options with different receptor activation profiles.

Each manufacturer's product has distinct pharmacokinetics and receptor-binding profiles. Semaglutide is a selective GLP-1 receptor agonist; tirzepatide is a GIP/GLP-1 receptor agonist; retatrutide is a GLP-1/GIP/glucagon receptor agonist. These mechanistic differences may influence efficacy and tolerability across different patient populations.

Branded vs. Compounded GLP-1 Formulations: Clinical and Access Considerations

Branded GLP-1 medications are FDA-approved and manufactured under strict pharmaceutical standards. Compounded GLP-1 medications are prepared by licensed 503A compounding pharmacies and are not FDA-approved as finished products. Both pathways serve different patient needs: branded drugs for those with insurance coverage, compounded formulations for cost-conscious patients or those seeking dosing flexibility.

Understanding the distinction matters for cost, availability, and clinical monitoring. Branded semaglutide (Wegovy) may cost $300+ monthly; compounded semaglutide typically ranges $149. Patients should discuss both options with providers to determine which aligns with their clinical needs and financial circumstances.

Formulation Type	Manufacturer Standard	Typical Cost Range	Primary Advantage
Branded Semaglutide (Wegovy)	Novo Nordisk, FDA-approved	$250–$500/mo	Insurance coverage, regulatory oversight
Branded Tirzepatide (Zepbound)	Eli Lilly, FDA-approved	$250–$550/mo	Dual-agonist mechanism, established safety data
Compounded Semaglutide Injection	Licensed 503A pharmacy	$149/mo	Lower cost, flexible dosing options
Compounded Tirzepatide Injection	Licensed 503A pharmacy	$249/mo	Accessible pricing, rapid uptake capability

How Genetic Factors in GLP-1 Pathways May Influence Treatment Selection

Individual genetic variation in GLP-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) genes may correlate with differences in baseline metabolism and peptide signaling capacity. Variants such as GLP1R rs6923761 and GIPR rs1800437 can help clinicians understand whether a patient's genetic profile aligns with selective GLP-1 or dual-agonist approaches.

The Precision Peptide Genetic Test evaluates predispositions in peptide genetic pathways—including GLP1R, GIPR, FTO, and MC4R variants—to provide context that may support a more informed provider conversation. Genetic insights do not predict exact medication response but may help tailor initial dosing, agonist selection, or monitoring intensity based on individual metabolic predisposition.

Safety, Eligibility, and Provider Guidance When Choosing GLP-1 Options

GLP-1 medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Patients with pancreatitis history, severe gastrointestinal disease, or those planning pregnancy should discuss GLP-1 use with their provider. Compounded formulations carry the same clinical considerations as branded versions; the source does not alter contraindication status.

A qualified healthcare provider should evaluate your medical history, current medications, and treatment goals before initiating any GLP-1 therapy. Genetic insights from the Precision Peptide Genetic Test should be interpreted alongside clinical assessment—not as a standalone decision tool. This integrated approach helps ensure the chosen formulation and dosing strategy align with your individual health profile and therapeutic objectives.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes that may provide context for how your body's peptide signaling pathways function at baseline. This information may help provide context when discussing with your provider whether a selective GLP-1 agonist, dual agonist, or other treatment aligns with your genetic predisposition. Results should always be interpreted with a qualified healthcare provider.

The genetic test does not predict exact medication response or guarantee which branded or compounded GLP-1 will work best for you. Instead, it reveals predispositions in peptide genetic pathways that can inform a more nuanced treatment conversation. For example, if your genetic profile suggests reduced FTO-mediated appetite signaling, your provider may tailor monitoring or dosing strategies differently than for someone with an alternate FTO variant.

When evaluating GLP-1 options—whether branded (Wegovy, Zepbound, Mounjaro) or compounded semaglutide and tirzepatide from PlexusDx—combining genetic context with clinical evidence, cost considerations, and provider expertise creates the most informed decision. PlexusDx compounded formulations start at $149/mo monthly and can be discussed alongside your genetic results and medical history to support a personalized treatment plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.